Shares of Elicio Therapeutics, Inc. (ELTX) tumbled 72% on Monday morning after the company reported that its Phase 2 AMPLIFY-7P study of ELI-002 7P in pancreatic cancer failed to meet its primary endpoint.
The stock is currently trading at $4.06, down $10.79 or 72.66%, on the Nasdaq. It opened at $4.79 after closing the previous session at $14.85. The stock has traded between $3.75 and $16.00 over the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Economic News
What parts of the world are seeing the best (and worst) economic performances lately? Click here to check out our Econ Scorecard and find out! See up-to-the-moment rankings for the best and worst performers in GDP, unemployment rate, inflation and much more.
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.